Alnylam Announces New Leadership Appointments
− Company Appoints Chief Human Resources Officer and Chief Scientific Officer –
“We are thrilled to have Kelley join our executive team and look forward
to working with her on building Alnylam for the future, including
acquisition of top talent, development of our leaders, and maintaining
our culture as we grow and scale,” said
"It’s wonderful to join Alnylam at a time when the Company is reaping the benefits of its innovation and has transitioned to commercialization of its potentially life-changing medicines. This transition, along with the advancement of the Company’s robust and diverse pipeline, will be enabled by continued investment in global growth, scalability, and people development. I hope to help foster this growth by ensuring that we are an employer of choice and that we continue to cultivate an inclusive and diverse culture conducive to forward thinking and innovation,” said Ms. Boucher.
In this role, Ms. Boucher will help guide organizational design and development, talent management, team effectiveness, culture, change management, and strategic talent acquisition – all while ensuring that Alnylam culture and philosophy are scalable and permeate the Company’s 26 current offices across 18 countries around the world.
Ms. Boucher comes with over 15 years of human resources and talent
acquisition/management experience in the biotech sector. Most recently,
Ms. Boucher was the Vice President (VP) and Head of Global Human
“It’s been a privilege to contribute to the growth of our rich pipeline and our Company’s evolution, having pioneered the translation of RNAi therapeutics from a Nobel Prize-winning discovery to a new class of medicines with the potential to transform the lives of thousands of underserved patients worldwide,” said Dr. Fitzgerald. “I am very excited to lead the discovery and development of the next wave of Alnylam’s RNAi therapeutics.”
In his role, Dr. Fitzgerald will be responsible for the strategic
direction and oversight of Alnylam’s discovery engine. He has over 20
years of experience in the context of small molecule and oligonucleotide
drug discovery. Dr. Fitzgerald’s tenure at Alnylam began in 2005 when he
joined as an Associate Director of Research. He has headed the Research
department since 2016. His achievements include leadership of Alnylam’s
RNAi delivery efforts, resulting in two clinically validated modes of
siRNA delivery, as well as the development of the Company’s
comprehensive clinical pipeline. He is an inventor on over 50 patents
that apply to the majority of Alnylam’s pipeline programs, and the
author of over 40 manuscripts, including many in prestigious journals
such as Nature, Cell, and
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of diseases with high unmet need. ONPATTRO® (patisiran) is the first-ever RNAi therapeutic approved by the U.S.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)